TECX
Tectonic Therapeutic, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.15
+2.42%Sep 29, 2026, 12:00 UTC
Tectonic Therapeutic announced favorable Phase 1a topline safety, tolerability and pharmacokinetic results for TX2100, an investigational antibody for hereditary hemorrhagic telangiectasia, and plans to start a Phase 1b trial by year-end 2026 and a Phase 2 trial in early 2027.
Source:Jun 10, 2026, 20:01 UTC
Tectonic Therapeutic completed enrollment in the TX45 APEX Phase 2 clinical trial for PH-HFpEF patients.
Source: